Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study
Oleksandr Korotych(World Health Organization Regional Office for Europe), Askar Yedilbayev(World Health Organization Regional Office for Europe), Līga Kukša(Riga East University Hospital), Myroslava Germanovych(World Health Organization Regional Office for Europe), Alena Skrahina(Republican Scientific and Practical Centre of Pulmonology and Tuberculosis), Ana Ciobanu(World Health Organization Regional Office for Europe), Jay Achar(South African Medical Research Council), Natalia Yatskevich(Republican Scientific and Practical Centre of Pulmonology and Tuberculosis), Elmira Gurbanova(University of Tartu), Naira Khachatryan(Ministry of Healthcare), Nino Lomtadze(National Center for Tuberculosis and Lung Disease), Nargiza Parpieva, Michael Rich, Giovanni Battista Migliori(Fondazione Salvatore Maugeri), İrada Akhundova, Rustam Nurov, Valentina Vilc(Phthisiopneumology Institute "Chiril Draganiuc"), Iana Terleieva(Ministry of Health), Arax Hovhannesyan(World Health Organization Regional Office for Europe), Saulius Diktanas, Malik Adenov(Kazakh Institute of Oncology and Radiology), Gunta Dravniece, Rovshen Jumayev, Nana Kiria(National Center for Tuberculosis and Lung Disease), Myahri Durdyeva(Turkmen State Medical University), Abdullat Kadyrov(Ministry of Health of Kyrgyzstan)
Cited by 23
Related Papers
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
|The Lancet Infectious Diseases|2017|688
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|321
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
|International Journal of Infectious Diseases|2020|226
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
|European Respiratory Journal|2019|176